Luciferase News and Research

RSS

Study: Drinking honeysuckle decoction accelerates the negative conversion of COVID-19 patients

In a new study in Cell Discovery, Chen-Yu Zhang's group at Nanjing University and two other groups from Wuhan Institute of Virology and the Second Hospital of Nanjing present a novel finding that absorbed miRNA MIR2911 in honeysuckle decoction (HD) can directly target SARS-CoV-2 genes and inhibit viral replication. Drinking of HD accelerate the negative conversion of COVID-19 patients.

7 Aug 2020

Stabilized prefusion spike vaccine candidate induces powerful immune response

A new research paper by scientists at Janssen Vaccines & Prevention BV, in the Netherlands and published on the preprint server bioRxiv* is based on the assumption that an effective vaccine against these infections will induce neutralizing antibodies and an immune response favoring Th1 immunity.

3 Aug 2020

New test rapidly determines neutralizing antibodies against Sars-Cov-2

To determine immunity to Sars-Cov-2 and the effectiveness of potential vaccines, the amount of neutralizing antibodies in the blood of recovered or vaccinated individuals must be determined.

30 Jul 2020

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

In a recent bioRxiv paper, a research group from the Marinomed Biotech biopharmaceutical company in Austria showed that a sulfated polysaccharide iota-carrageenan has the propensity to inhibit cell entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using an in vitro neutralization assay.

29 Jul 2020

Cat catches coronavirus from owners

Cases of pet animals contracting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported since the coronavirus disease (COVID-19) first emerged. Now, a pet cat has become the first animal in Britain to test positive after contracting the virus from its owners.

28 Jul 2020

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Researchers from the National Institutes of Health (NIH) and Cornell University in the U.S. just described several new inhibitors of human coronavirus spike proteins by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Their exciting findings are currently available on the bioRxiv preprint server.

13 Jul 2020

Research shows how SARS-CoV-2 alters translation

Now, a new study published on the preprint server bioRxiv in July 2020 shows that the 5’ end of the RNA molecule is capable of inhibiting the binding of mRNA to the ribosomal 40S subunit, thus preventing translation.

9 Jul 2020

A biomaterial vaccine for SARS-CoV-2 - quick and scalable

A recent 'tour-de-force' research endeavor, led by scientists from Harvard University, explored the propensity of a biomaterial vaccine based on mesoporous silica rods to spawn highly protective humoral responses against relevant antigens of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2020

New assay rapidly tests SARS-CoV-2 neutralization and screens antivirals

Researchers at the University of Texas Medical Branch, Galveston, have developed a new platform that can rapidly test neutralizing antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and perform high-throughput screening of potential antiviral agents.

24 Jun 2020

Interesting study on which species may be infected by SARS-CoV-2

The team from the University of Cambridge and the Pirbright Institute found that the Spike protein on SARS-CoV-2 engages with the host cell receptor angiotensin-converting enzyme 2 (ACE2) across a wide range of animals, even though the Spike binding site shows a between-species variation in its amino acid composition.

21 Jun 2020

Mutational targets of SARS-CoV-2 receptor-binding domain for vaccine-antiviral development

The COVID-19 pandemic has spread throughout the whole world within six months, causing millions of infections and hundreds of thousands of deaths. Yet there is no effective vaccine or antiviral to deal with it.

18 Jun 2020

Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2

US researchers have published a proof of concept on the efficacy of human monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in laboratory conditions, as well as their pioneering use in a mouse model. The study is available on the preprint server bioRxiv*.

17 May 2020

New information on viral antigens could improve COVID-19 testing

Researchers in France and China have characterized antibody responses to a wide range of antigens present on severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) among patients with coronavirus disease 2019 (COVID-19).

4 May 2020

Discovery of first blue light emitting South American insect

A rainforest reserve, bordering the mighty Atlantic, in the Sao Paulo state of Brazil, is now in the news because scientists saw a flash of blue while they were gathering mushrooms. Indeed, this privately-owned Reserva Betary park can boast the honor of being host to the newly discovered species of fungus gnat, named Neoceroplatus betaryiensis, the larva of which is the first bioluminescent creature found in the Neotropics that emits blue light.

31 Oct 2019